Phase I/IIa, First-in-human, Open-label, Dose Escalation Trial With Expansion Cohorts to Evaluate Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BNT151 as a Monotherapy and in Combination With Other Anti-cancer Agents in Patients With Solid Tumors
Latest Information Update: 10 Jul 2024
At a glance
- Drugs BNT 151 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors BioNTech
Most Recent Events
- 26 Jun 2024 Status changed from active, no longer recruiting to discontinued as per sponsor decision.
- 08 Apr 2024 Planned End Date changed from 1 Jun 2026 to 31 May 2024.
- 08 Apr 2024 Planned primary completion date changed from 1 Feb 2024 to 31 May 2024.